Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Good Energy margin gains drive annual profits higher

(Sharecast News) - A significant improvement in margins at Good Energy was able to offset a big slump in revenues, with the renewable electricity and energy services provider reporting a double-digit increase in profits for 2024. The company, which in January agreed to a £99m takeover from Esyasoft, said on Friday that pre-tax profits totalled £6.6m last year, up 16% on 2023.

Revenues, which are directly linked to externally driven commodity costs, fell to £180.1m from £254.7m. Both revenues and the cost of sales reduced, mirroring reductions in wholesale costs seen since the 2022/2023 peaks, the company said.

However, gross margins rose to 24.4%, up 7 percentage points over the previous year.

Cash and cash equivalents fell to £28.6m from £41.3m, as £5m of inflows from operational activities were offset by £18m of cash outflows mainly due to investment activities linked to the purchase of three new service installation businesses during 2024.

"As Good Energy embarks on a new chapter, we can report another strong year both financially and strategically. 2024 saw the business make three further acquisitions, significantly scaling our services for solar installation across the nation," said chief executive Nigel Pocklington.

Meanwhile, chair Will Whitehorn said: "I want to thank all of our shareholders for their support in this journey, as we have seen substantial growth in the value of the company, realised now through the impending acquisition by Esyasoft."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.